Rinsho Ketsueki
Online ISSN : 1882-0824
Print ISSN : 0485-1439
ISSN-L : 0485-1439
Retrospective Analysis of Elderly Patients ≥60 years of age with Acute Leukemia
Masahiko TABATA, Minoru YOSHIDA, Toru IZUMI, Chizuru KAWANO, Ryoko KURIBARA, Masaki TOSHIMA, Ken OMINE, Masaaki TAKATOKU, Mie UCHIDA, Keita KIRITO, Akira MIYAZATO, Hironori TAKAHASHI, Mitsuaki HOSHINO, Yasuhito TERUI, Hiroshi TOMIZUKA, Tetsuya OTSUKI, Ritsuko SHIMIZU, Jyun-ichi TSUNODA, Kazuo MUROI, Yusuke FURUKAWA, Youichi AMEMIYA, Shigehiko IMAGAWA, Norio KOMATSU, Toshiyuki SUZUKI, Ryuhei SASAKI, Kiyohiko HATAKE, Yasusada MIURA
Author information
JOURNAL RESTRICTED ACCESS

1998 Volume 39 Issue 3 Pages 176-184

Details
Abstract
A retrospective analysis was performed on 76 consecutive elderly patients with acute leukemia aged 60 years or more (48 men, 28 women). Forty patients were 60∼69 years old, 28 were 70∼79 years old and 8 were ≥80 years old. There were 55 patients with acute myelogenous leukemia (AML), 13 acute lymphoblastic leukemia (ALL) and 8 AML from myelodysplastic syndrome (MDS/AML). Patinets were treated with the JALSG protocol, CAG regimen, or low-dose Ara-C regimen for AML and DVP/M-CHOP protocol for ALL. The complete remission (CR) rates were 52.7% (29 of 55) in AML, 61.5% (8 of 13) in ALL, and 0% in MDS/AML. The median CR durations were 226, 85, 0 days, and the median survivals were 204, 177, 99 days, respectively. CR rates were 65.3% for the JALSG protocol, 62.5% for the CAG regimen and 25.0% for low-dose Ara-C regimen. According to age, CR was obtained 62.5% in patients aged 60∼69 years and 33.3% in patients over 70 years old. Our results indicated that patients aged 60∼69 years should be treated with intensive chemotherapy.
Content from these authors
© 1998 The Japanese Society of Hematology
Previous article Next article
feedback
Top